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A B S T R A C T
BACKGROUND & AIMS: Hydroxychloroquine (HCQ) and chloroquine (CQ) are anti-malarial drugs
frequently used in the rheumatologic field. They were recently identified as potential therapeutic options
for Coronavirus Disease (COVID-19). The present study aims to map and grade the diverse health
outcomes associated with HCQ/CQ using an umbrella review approach.
METHODS: Umbrella review of systematic reviews of observational and intervention studies. For
observational studies, random-effects summary effect size, 95% confidence interval, and 95% prediction
interval were estimated. We also assessed heterogeneity, evidence for small-study effect, and evidence
for excess significance bias. The quality of evidence was then graded using validated criteria from highly
convincing to weak. The evidence from randomized controlled trials (RCTs) was graded using the Grading
of Recommendations, Assessment, Development and Evaluation (GRADE) tool.
RESULTS: From 313 articles returned in the literature search, six meta-analyses were included (n = 25
outcomes). Among meta-analyses (MAs) of observational studies, HCQ/CQ are weakly associated with a
reduced risk for cardiovascular events and diabetes when used for autoimmune diseases and with
spontaneous abortion; they are also associated with a higher risk of death in COVID-19 patients. Among
MAs of RCTs, HCQ/CQ are associated with an improvement of articular manifestations of rheumatic
diseases.
CONCLUSIONS: There is high evidence of the efficacy of HCQ/CQ in the rheumatologic field. The lack of
evidence for efficacy and the risk of death associated with the use of HCQ/CQ for COVID-19 indicate the
inappropriateness of their inclusion in recent COVID-19 therapy guidelines and the urgent need for RCTs
to determine eventual appropriateness as a COVID-19 therapy.
© 2020 Published by Elsevier Ltd on behalf of International Society for Infectious Diseases. This is an open
access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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ystemic lupus erythematosus (Fanouriakis et al., 2019) and are
lso considered for the treatment of other autoimmune diseases,
uch as antiphospholipid syndrome (Tektonidou et al., 2019),
jogren’s syndrome (Ramos-Casals et al., 2020), and rheumatoid
rthritis (Smolen et al., 2020).
Recent results from 15 trials reported by Chinese researchers
ndicate a potential role for HCQ/CQ with the new coronavirus
isease (COVID-19) (Yao et al., 2020). Despite limited clinical data
n the use of HCQ/CQ in COVID-19, the use of these drugs has
ttracted considerable attention from the media. Individuals and
obby groups have called for widespread prescription of these
rugs (Javelot et al., 2020). Public endorsement of the use of HCQ
nd other medications (e.g., azithromycin) to treat COVID-19 has
ed to it becoming one of the most used treatments in this
andemic (Ferner and Aronson, 2020; Jaffe, 2020).
Currently, more than 200 trials of HCQ, CQ, or both, and
ometimes in combination with other drugs, are registered
orldwide. The translation from laboratory to clinic has led to
isappointment, likely due to the complex pharmacokinetics of 4-
minoquinolones, with scarce effects obtained so far (Ferner and
ronson, 2020). In some cell cultures CQ inhibits dengue, shows
romising effects on Ebola and influenza virus, and has some
ffects on SARS-CoV2 (Ferner and Aronson, 2020; Yao et al., 2020).
From a public health perspective, the side effects, as well as the
otential benefits, need to be considered before clinicians expose
heir patients to these drugs. Wide use of HCQ/CQ may expose
ome patients to harm, ranging from cutaneous adverse reactions
o hepatic failure and ventricular arrhythmias, which occur
specially when HCQ/CQ is associated with other medications,
uch as azithromycin (Ferner and Aronson, 2020; Mercuro et al.,
020).
The aim of the present work is to evaluate – through an
mbrella review – the strength and credibility of the evidence
erived from systematic reviews with meta-analyses (MAs) of
bservational and intervention studies regarding HCQ/CQ, their
mportance to health outcomes and their side effects.
ethods
The protocol for this review was registered in PROSPERO on 1
pril 2020 in the context of COVID-19 research and is still awaiting
ormal approval. The submitted protocol is attached in the
upplementary Material.
ata sources and searches
We conducted an umbrella review (Ioannidis, 2009), searching
he MEDLINE, Scopus and Embase databases from inception until
7 June 2020 with:
“(Meta-Analysis [ptyp] OR metaanaly*[tiab] OR meta-analy*
tiab] OR Systematic review [ptyp] OR “systematic review” [tiab])
ND (Hydroxychloroquine [tiab] OR Hydroxychlorochin [tiab] OR
chloroquine” [tiab] OR Plaquenil [tiab] OR “Hydroxychloroquine
ulfate” [tiab] OR “Hydroxychloroquine Sulfate (1:1) Salt” [tiab]).
We also hand-searched the reference lists of eligible articles
nd reviews in this field.
tudy selection
HCQ/CQ. The study selection was made by two authors indepen-
dently (JD, SC). Disagreements were resolved through consensus
with an independent author (NV). Full-texts of all potentially
eligible articles were subsequently evaluated by the same two
authors (JD, SC) and any disagreement resolved with another
independent author (LS).
MAs were included only if they reported study-specific
information (i.e., effect size, 95% confidence intervals (CIs), sample
size) or if those metrics could be inferred from the data presented.
Data extraction
For each eligible MA, two independent investigators (JD, SC)
firstly extracted data from each eligible MA including: name of first
author; year of publication; study population; study design;
outcome; number of studies; intervention; comparison; and effect
size reported with 95% CI.
The same two authors (JD, SC) then extracted the following
information for each original article: PMID/doi; name of MA
author; year of MA; name of first author of single studies included
in the MA; year of publication; population/main condition of
patients exposed to HCQ/CQ; effect size metrics used in the MA;
study design of included primary studies (e.g., case-control,
prospective, RCT); number of cases and controls for each study;
number of people treated with HCQ/CQ with the correspondent
number of events and number of people in placebo/control and
corresponding number of events in intervention MAs; follow-up;
mean age of participant population; medication type (HCQ, CQ);
and outcome.
Next, the study-specific estimated relative risk for any side
effects or negative outcome were extracted with 95% CI (risk ratio,
odds ratio (OR), hazard ratio, incident risk ratio, standardized mean
differences, and mean differences (MDs)).
If two MAs were available for the same outcome, the one that
included the largest number of studies (or if equal for number of
studies, the most recent one) was used. If there were observational
and RCT MAs investigating the same outcome, both were included.
Outcomes
Any health outcome, adverse event or side effect potentially
associated to HCQ/CQ therapy.
Risk of bias assessment
The methodological quality of each included MA was assessed
by two independent investigators (LS, SC) with the Assessment of
multiple systematic reviews (AMSTAR) 2 tool (https://amstar.ca/
Amstar-2.php). A recent update of AMSTAR (Shea et al., 2017),
AMSTAR2 ranks the quality of a MA from critically low to high
according to 16 predefined items.
Data synthesis and analysis
For each MA we estimated the summary effect size and its 95%
CI through a random-effects model. We also estimated the
prediction interval (PI) and its 95% CI, which further accounts
for between-study effects and estimates the certainty of the
association if a new study addresses the same association (Higgins
et al., 2009; IntHout et al., 2016; Serghiou and Goodman, 2018).We considered eligible: 1) any MA that included people of any
ge, any risk category, any population, taking any HCQ/CQ
edication; 2) MAs of longitudinal design studies (i.e., prospec-
ive/cohort or retrospective/case-control) that investigated the
ssociation of HCQ/CQ administration with any outcome or MAs of
andomized controlled trials (RCTs) that investigated the effects of60Between-study inconsistency was estimated with the I2 metric,
with values >50% indicative of high heterogeneity and >75% very
high heterogeneity (Higgins and Thompson, 2002). We calculated
the evidence of small-study effects (i.e., whether small studies
inflated effect sizes) using the regression asymmetry test (Egger
et al., 1997) with a p-value of <0.10 (Carvalho et al., 2016). Finally,0
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2007). Because of the limited statistical power of this test a lenient
significance threshold (p < 0.10) was adopted (Ioannidis, 2013). We
considered the effect size of the largest dataset and based on this
we estimated the power of each constituent study with an
algorithm using a non-central t distribution. Excess significance for
each MA was considered whenever p <0.10.
We planned to run several sensitivity analyses (age, duration of
therapy/exposure), however, these data were not sufficiently
reported in the MAs included, hindering reliable analyses.
All statistical analyses were conducted in Stata, version 14.0
(StataCorp), and R, version 3.3.0 (R Foundation for Statistical
Computing).
Grading the evidence
For observational studies, using the criteria mentioned above,
significant associations (i.e., p <0.05) were categorized into strong,
highly suggestive, suggestive, or weak evidence, following a
grading scheme that has already been applied in various fields
(Theodoratou et al., 2014; Aromataris et al., 2015; Belbasis et al.,
2016; Bellou et al., 2016; Dinu et al., 2017; Kyrgiou et al., 2017; Li
et al., 2017; Veronese et al., 2018; Solmi et al., 2020).
Grading of Recommendations, Assessment, Development and
Evaluation (GRADE) assessment of observational studies was
performed (supplementary table 1 GRADE of observational
studies). Based on the GRADE assessment of observational studies
(mostly case control), independently from significance of associa-
tion, one was rated as moderate (Singh et al), nine were rated as
low, and all the remaining as very low quality. The rating was
impaired mostly due to heterogeneity, unavailable data, and
quality assessment of original studies.
Evidence from MAs of RCTs was assessed in terms of the
significance of the summary effect, using a p-value <0.05 as the
threshold for statistical significance. When the p-value for the
random effect was <0.05, we evaluated the evidence using the
GRADE assessment (Guyatt et al., 2008). We also reported 95% PI
(excluding null or not), the presence of large heterogeneity (I2
>50%), small study effects (p >0.10), and excess significance (p
>0.10) as possible indicators of quality of the available evidence.
Results
Literature review
The initial search yielded 313 articles. After duplicates (61) were
removed we evaluated 252 papers. Only 62 papers were eligible forFigure 1. Flow of studies through review selection.
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Table 1
Findings from the observational studies.



























HCQ RA DM incidence 3 273 16,885 HR 0.59 0.49 0.7 1.04E-
08
0 no no yes 0.18 1.92 IV
HCQ Autoimmune disease CVD 7 NA 3447 OR 0.43 0.26 0.71 0.001 50.2 yes NA NA 0.1 1.79 IV
HCQ/CQ Autoimmune disease CVD 10 NA NA RR 0.73 0.56 0.94 0.01 42.8 no NA NA 0.38 1.89 IV
HCQ Autoimmune disease +
pregnancy
Spontaneous abortion 4 82 1090 OR 1.86 1.1 3.14 0.02 12.3 no no yes 0.45 7.68 IV
HCQ Autoimmune disease +
pregnancy (no APLS)
Spontaneous abortion 4 79 1055 OR 1.77 1.09 2.89 0.02 0 no no yes 0.61 5.18 IV
HCQ/CQ SLE CVD 7 NA NA OR 0.71 0.53 0.96 0.03 43.5 no NA NA 0.34 1.5 IV
HCQ Autoimmune disease +
pregnancy
Prematurity 5 260 1343 OR 1.75 0.95 3.23 0.07 71.6 no no yes 0.21 14.29 NS
HCQ Autoimmune disease +
pregnancy
LBW 2 83 252 OR 0.88 0.22 3.6 0.1 62.1 NA no no NA NA NS
HCQ SLE pregnancy Prematurity 6 230 871 OR 0.58 0.29 1.16 0.12 46.7 no no no 0.09 3.54 NS
HCQ SLE pregnancy IUGR 5 143 831 OR 0.6 0.22 1.64 0.32 69.1 no no no 0.03 14.2 NS
HCQ Autoimmune disease +
pregnancy
Stillbirth 4 41 1467 OR 0.72 0.36 1.41 0.33 0 no no no 0.24 2.18 NS




5 4 1295 OR 1.9 0.32 11.31 0.48 0 no no no 0 20,000 NS




5 5 1295 OR 0.63 0.13 3.2 0.58 0 yes no no 0.02 22.22 NS




5 12 1295 OR 1.41 0.42 4.67 0.58 0 no no no 0.01 19.59 NS




7 58 1800 OR 1.12 0.58 2.15 0.74 17 no no no 0.3 4.19 NS




5 15 1295 OR 1.06 0.29 3.86 0.93 0 no no no 0.06 18.12 NS
HCQ COVID-19 Death 2 52 446 OR 1.84 0.74 4.55 0.19 40.7 NA NA yes NA NA NS
Abbreviations: HCQ: Hydroxychloroquine; CQ: chloroquine; RA: Rheumatoid arthritis; APLS: Antiphospholipid syndrome; SLE: Systemic Lupus Erythematosus; DM: Diabetes Mellitus; CVD: Cardiovascular disease; LBW: Low birth
























S. Celotto, N. Veronese, M. Barbagallo et al. International Journal of Infectious Diseases 103 (2021) 599–606full text screening. As reported in the PRISMA flow-chart (Figure 1),
we identified six MAs as eligible: Suarez-Almazor et al., 2000;
Kaplan et al., 2016; Guillotin et al., 2018; Liu et al., 2018;
Rempenault et al., 2018; and Singh et al., 2020.
Meta-analyses of observational studies
As shown in Table 1, the MAs of the observational studies
included 17 outcomes. Two outcomes included HCQ/CQ, whilst the
other 15 included only HCQ. Most (16/17) of the outcomes included
patients with autoimmune diseases, including during pregnancy
(n = 10 outcomes). As a consequence, obstetrical outcomes were
the most frequently included. One other outcome was mortality in
people with COVID-19. The median number of studies included
was five (range: 2–10), the median number of events was 93
(range: 4–273), and the median sample size was 2311 (range:
25216,885).
Only four outcomes reported a high heterogeneity, with an I2 of
50–75%. The small-study effect was present in 2/17 of the
outcomes included, whilst no outcome presented excess signifi-
cance bias. Four of the 17 outcomes presented the largest studies in
terms of a statistically significant number of participants (p < 0.05).
None of the outcomes included had 95% PI, excluding the null.
Using the criteria mentioned before, 7/17 outcomes reported a
statistically significant effect size (p < 0.05) and were all rated as
weak. One outcome reported a higher risk of death in people with
COVID-19. Three outcomes reported a lower incidence of
cardiovascular disease (CVD) in patients with autoimmune
diseases, one outcome showed a lower incidence of type 2
diabetes in patients with rheumatoid arthritis, and two outcomes
revealed a higher rate of spontaneous abortion in women with
autoimmune rheumatologic conditions.
Meta-analyses of randomized controlled trials versus placebo
Eight outcomes were explored by the RCTs with a placebo as the
control group. No outcome presented active medications as the
control group.
Table 2 reports descriptive findings regarding the MAs of
the RCTs. Only one condition was included, rheumatoid arthritis
(n = 8).
As shown in Table 3 we found that the use of HCQ/CQ compared
to placebo was associated with an improvement of the measure of
articular inflammation, i.e. a lower number of swollen joints (n = 4
RCTs; MD -3.71; 95% CI: -4.86 to -2.57) with a high certainty of
evidence. HCQ/CQ was also associated, when compared to placebo,
to a lower incidence of withdrawals and dropouts (0.58; 95% CI:
0.400.86), and also to lower withdrawals and dropouts due to
lack of efficacy (OR 0.54; 95% CI: 0.32-0.92). A moderate certainty
of evidence was present for improvement in the clinician’s global
assessment of the disease and of subjective measures of
inflammation, the number of painful joints (namely, tender joints).
A low grade of evidence was found for improvement in the
patient’s global assessment of the disease.
Risk of bias
The assessment of the risk of bias in the MAs included is
reported in Supplementary Table 1. Four MAs were rated as
critically low, with two rated low. The main reasons for these
ratings were the absence of a list of excluded studies (item 7), poor
information regarding the source of funding in the studies
included (item 10), and the lack of assessment of publication bias
(item 15).
Discussion
In this umbrella review, we report the current research
regarding HCQ/CQ in humans, including its efficacy and tolerability
in rheumatologic disorders, its safety during pregnancy, and its
impact on viral diseases. Overall, our findings suggest that these
medications are useful in the treatment of rheumatologic
conditions, and their use is associated with adverse events when
administered for viral diseases. We believe that our findings are
important for the current COVID-19 pandemic.
HCQ/CQ in rheumatology
The efficacy of HCQ/CQ in rheumatoid arthritis has been
confirmed and supported by our study showing an improvement in
the number of swollen and tender joints, and in the clinician’s
global assessment of the disease. As an additional effect, we found
Table 2
Descriptive (and ancillary) findings of the meta-analyses of the randomized controlled trials.



















RA Swollen joints 4 290 281 571 MD 3.71 4.86 2.57 2.21E-
10
0 no yes 6.23 1.2
RA Physician global
assessment
2 185 180 365 MD 0.39 0.56 0.21 0.00002 0 NA yes NA NA
RA Tender joints 4 290 281 571 MD 2.66 4.19 1.13 0.001 0 yes no 6.01 0.69
RA Withdrawals and
dropouts
4 299 292 591 OR 0.58 0.4 0.86 0.006 4.8 no no 0.23 1.59
RA Withdrawals and
dropouts lack of efficacy
4 235 232 467 OR 0.54 0.32 0.92 0.02 7.9 no no 0.01 24.54
RA Patient global assessment 4 185 180 365 MD 0.41 0.77 0.05 0.03 51.4 NA yes NA NA
RA Pain 4 247 237 484 MD 3.75 7.8 0.3 0.07 88.2 no yes 51.35 48.35
RA Withdrawals AE 4 297 289 586 OR 0.81 0.38 1.69 0.57 0 yes no 0.16 4.1
Abbreviations: HCQ/CQ: Hydroxychloroquine/Chloroquine; RA: Rheumatoid arthritis; AE: Adverse Events; GI: Gastrointestinal.Four RCTs were included with a median number of participants
of 528 (in median, 269 randomized to HCQ/CQ and 259 to placebo).
The largest study was statistically significant in 4/8 outcomes and
one outcome included a 95% PI (lower number of swollen joints).
Overall, 6/8 outcomes were statistically significant and conse-
quently rated using the GRADE.603that HCQ/CQ is able to reduce the incidence of type 2 diabetes in
patients with rheumatoid arthritis. This effect might be explained
by a decrease in insulin clearance and degradation rate, and an
increase in the secretion of C-peptide (Powrie et al., 1991; Emami
et al., 1998). The role of HCQ/CQ should be considered while
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ollow-up compared to placebo, implying that HCQ/CQ is a
enerally well tolerated treatment even in the long term. In
eneral, considering their use in rheumatic diseases, we confirmed
he efficacy of HCQ/CQ in reducing CVD risk, probably due to the
mmunomodulatory and anti-thrombotic effect of these drugs
Petri, 2011). Different mechanisms of action are deemed to be
1994) and a reduction of dyslipidemia and atherosclerosis was
demonstrated in an animal model (Shi et al., 2019). These might
explain the impact on the cardiovascular system and arguably
represent the reason why its role in COVID-19 was considered
initially, since many of the mechanisms involved are shared with
SARS-CoV-2 infection (Yang et al., 2020).
able 3
ffect of hydroxychloroquine and/or chloroquine in rheumatoid arthritis.esponsible for these effects, namely the reduction of platelet
ggregation (Kinlough-Rathbone, 1975), the increase in blood
uidity (Ernst et al., 1984), and the inhibition of prothrombotic
echanism mediated by antiphospholipid antibodies (Espinola
t al., 2002). The anti-inflammatory action of HCQ/CQ is developed
hrough the reduction of factors such as IL-6 and TNF-α (Wallace,60HCQ/CQ in pregnancy
HCQ/CQ seem to be safe in pregnancy, as also confirmed by our
findings, even if our work found an increase of spontaneous
abortion in women taking HCQ/CQ. An increase in the risk of
premature delivery and intrauterine growth restriction has been4
S. Celotto, N. Veronese, M. Barbagallo et al. International Journal of Infectious Diseases 103 (2021) 599–606seen, however, these associations are not significant. The increase
of spontaneous abortion is more likely to be attributed to the
underlying autoimmune diseases rather than drug consumption
(Bundhun et al., 2017). In rheumatic diseases HCQ is commonly
used during pregnancy (Birru Talabi and Clowse, 2020). HCQ is
recommended in systemic lupus erythematosus pregnancies to
control disease flares and reduce the risk of poor obstetrical
outcomes, however, more data are needed to support the use of
HCQ during pregnancy in patients with antiphospholipid syn-
drome (Andreoli et al., 2017).
HCQ/CQ in COVID-19
In this paper we highlight the absence of any evidence supporting
the broad use of HCQ/CQ to treat viral diseases, while suggesting a
higher risk of death when used for treating COVID-19 (Singh et al.,
2020). Recently HCQ/CQ was used, alone or in combination with
azithromycin, for treating COVID-19 in both hospitals and primary
care settings, based on the promising results it had in vitro (Yao et al.,
2020). However, to date, there is no evidence of efficacy, since the
only outcome that could be considered as a proxy (the reduction of
viral load) was not statistically significant. As shown in a recent
systematic review, the findings regarding COVID-19 are sparse
overall and the few intervention studies available are of poor quality
(Cortegiani et al., 2020).
A recent large observational study (Geleris et al., 2020) on 1776
hospitalized consecutive patients, shows that HCQ administration
neither increases nor decreases the risk of intubation or death in
COVID-19.
The administration of HCQ/CQ should be carefully evaluated, as it
is known to have several side effects, the most worrisome being
cardiovascular (torsade de pointes consequent to QTc prolongation)
and ocular (bulls-eye retinopathy) (Ben-Zvi et al., 2012). Proper
dosing of maximum 5 mg/kg/die and regular screening according to
risk factors are considered necessary for minimizing the risk of
adverse reactions (Kim et al., 2017). The extensive use of HCQ,
especially in combination with azithromycin, may increase the risk
of QTc prolongation and eventually torsade de pointes (TdP) and
death(Javelotetal.,2020).Manyexperts considermonitoringtheQTc
interval as mandatory due to HCQ’s well-known arrhythmogenic
cardiotoxicity (Haeusler et al., 2018), and monitoring electrolytes,
particularly in those already on treatment with beta-blockers or
calcium channel blockers (Page et al., 2016), since hypokalaemia,
frequently described in COVID-19, predisposes to patients to cardiac
conduction disorders (Xu et al., 2020). However, only a few clinical
studies have analyzed the cardiovascular effects of HCQ/CQ (Hancox
et al., 2013). In a large cohort of COVID-19 patients treated with HCQ/
CQ, with or without azithromycin, no instances of TdP or
arrhythmogenic death were reported and although the use of these
medications resulted in QTc prolongation clinicians seldom needed
to discontinue therapy (Saleh et al., 2020).
There is a need for high quality RCT studies to define more
precisely the role of HCQ/CQ during the COVID-19 pandemic.
Considering the side-effects that HCQ/CQ may be responsible for,
and the lack of evidence for success in improving the prognosis of
COVID-19 patients, it may be considered as inappropriate to
include HCQ/CQ in the current guidelines or protocols for
treatment of COVID-19.
Limitations
best-evidence grade only to robust associations without hints of
bias. However, I2 estimates can also carry substantial uncertainty
and clinical heterogeneity may be substantial even in the absence
of statistical heterogeneity. It is known that MAs have considerable
limitations (Ioannidis, 2016) and their results depend on the choice
of the estimate from each primary study and its representation in
the MA (e.g., in the included MA clarity about duration of the
studies and the dosage of HCQ/CQ were missing). Applying the
criteria suggested by the AMSTAR 2 for evaluating the quality of
MAs, we observed the presence of low/critically low ratings,
highlighting several potential biases. This evidence is mainly
driven by missing information in item 2 (protocol published before
the MA), 7 (list of excluded studies), or 15 (publication bias
quantitative synthesis was not performed).
Conclusions
In conclusion, in this umbrella review including six meta-
analyses and 25 outcomes, we confirmed that HCQ/CQ has an
important role in rheumatoid arthritis, reducing joint pain and
swelling and lowering the incidence of type 2 diabetes. When used
for autoimmune diseases it lowers CVD risk. We also found that
HCQ/CQ is associated with an increase of spontaneous abortion,
though this may be due to the underlying autoimmune disease
more than the pharmacological therapy (Bundhun et al., 2017).
When used for treating COVID-19, HCQ/CQ seems to be associated
with a higher risk of death. These aspects should be taken into
consideration before widespread utilization of HCQ, even when
pre-clinical results suggest its usefulness, as a therapy for new, and
still unknown, viral diseases.
The results of our study highlight the lack of evidence and the
presence of side effects associated with the use of HCQ/CQ for viral
diseases, including COVID-19, indicating the urgent need for RCTs
to determine their eventual appropriateness as a therapy for
COVID-19.
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Appendix A. Supplementary data
Supplementary material related to this article can be found, in
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